Avanos Medical director shares cashed out at $25
Avanos Medical, Inc. director Julie Ann Shimer reported issuer dispositions tied to the closing of a merger effective July 27, 2026.
Rhea-AI Filing Summary
Avanos Medical, Inc. director Julie Ann Shimer reported issuer dispositions tied to the closing of a merger effective July 27, 2026. 50,090 shares of common stock were converted into the right to receive $25.00 per share in cash under the merger agreement. In a related step, 12,003 restricted share units were canceled and converted into a cash payment based on the same merger consideration, less applicable taxes. After these transactions, Shimer reported no remaining common stock or restricted share unit holdings.
Positive
- None.
Negative
- None.
Insights
Analyzing...
Insider Trade Summary
Disposition: 62,093 shares
Disposition
2 txns
Insider
Shimer Julie Ann
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Restricted Share Units F2, F3 | 12,003 | $25.00 | $300K |
| Disposition | Common Stock F1 | 50,090 | $25.00 | $1.25M |
Holdings After Transaction:
Restricted Share Units — 0 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (3)
- F1. Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026 (as it has been or may be amended, supplemented, waived or otherwise modified in accordance with its terms, the Merger Agreement), by and among the Issuer, A-AV Holdco I, Inc., a Delaware corporation, and A-AV MergerSub, Inc. (Parent), a Delaware corporation and a wholly-owned subsidiary of Parent, each share of the Issuer's common stock, par value $0.01 per share, that was issued and outstanding immediately prior to the effective time of the merger (the Merger), which occurred on July 27, 2026, was converted into and exchanged for the right to receive $25.00 per share in cash, without interest (the Merger Consideration), payable in accordance with the terms and subject to the conditions of the Merger Agreement.
- F2. Represents restricted share units issued to the Reporting Person on May 8, 2026. Each restricted share unit represents a contingent right to receive a cash payment equal to the value of one share of the Issuer's common stock.
- F3. Pursuant to the Merger Agreement, these cash-settled restricted share units were canceled immediately prior to the Effective Time of the Merger and converted into the right to receive an amount in cash determined by multiplying: (i) the Merger Consideration by (ii) the number of shares of Common Stock subject to the restricted share unit award (less applicable tax withholdings).
Key Figures
Common shares converted: 50090 shares
Restricted share units canceled: 12003 restricted share units
Merger Consideration: $25.00 per share
+2 more
5 metrics
Common shares converted
50090 shares
Common stock converted to cash at $25.00 per share on July 27, 2026
Restricted share units canceled
12003 restricted share units
Cash-settled RSUs canceled and converted to cash based on merger consideration
Merger Consideration
$25.00 per share
Cash paid for each issued and outstanding common share at the merger effective time
Post-transaction holdings
0.0000 shares
Reported holdings of both common stock and RSUs after merger-related dispositions
Disposition transactions
2 transactions
Both reported with code D as dispositions to issuer on July 27, 2026
Key Terms
Agreement and Plan of Merger, Merger Consideration, restricted share units, cash-settled restricted share units
4 terms
Agreement and Plan of Merger regulatory
"Pursuant to the Agreement and Plan of Merger, dated as of April 13, 2026..."
An Agreement and Plan of Merger is a formal document where two companies agree to combine into one, outlining how the process will happen. It’s like a step-by-step plan for merging, and it matters because it shows both sides have agreed on the details before the official transition takes place.
Merger Consideration financial
"was converted into the right to receive $25.00 per share in cash... (the Merger Consideration)"
Merger consideration is the total payment a company or buyer offers to shareholders of a target company in exchange for combining the two businesses, and can include cash, shares in the surviving company, debt assumption, or a mix of these. Investors care because the form and amount affect the deal’s value, tax consequences, immediate cash received versus future ownership, and the risk and upside of holding new shares — similar to choosing between cash now or stock that could grow later.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did AVNS director Julie Ann Shimer report in this Form 4?
Julie Ann Shimer reported issuer dispositions connected to a merger, where 50,090 common shares and 12,003 restricted share units were converted into cash based on $25.00 per share merger consideration, leaving her with no reported remaining holdings.
Does Julie Ann Shimer still hold Avanos Medical (AVNS) equity after the merger?
The reported post-transaction holdings are 0.0000 shares of both common stock and restricted share units. This indicates that, after the merger-related conversions and cancellations, Shimer had no remaining Avanos Medical equity reported in this Form 4.
Were Shimer’s AVNS transactions executed under a Rule 10b5-1 trading plan?
The filing’s Rule 10b5-1 affirmation box is not checked, and the footnotes describe merger-driven conversions rather than discretionary trades. The transactions are reported as mechanical results of the merger agreement, not as a pre-arranged trading plan.
What triggered the insider transactions reported for AVNS on July 27, 2026?
The transactions were triggered by the closing of a merger on July 27, 2026. Under the merger agreement, each issued and outstanding Avanos Medical common share was converted into a right to receive $25.00 per share in cash, driving the reported dispositions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
